Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company applying artificial intelligence to drug discovery and therapeutic product development. Founded in 2023, the company emerged from stealth mode in 2024 with over $1 billion in funding. Its technical domains span AI, protein design, and data generation for therapeutic applications, operating at the intersection of computational biology and pharmaceutical development.

The company maintains a geographic presence in South San Francisco, Seattle, and London. Xaira operates within the biotechnology and pharmaceutical verticals, positioning its AI-driven platform as a tool for accelerating the identification and optimization of therapeutic candidates. The scale of its capitalization at stealth exit signals the computational and experimental infrastructure required for large-scale protein design and drug discovery pipelines.

For robotics and automation engineers, the company's work in AI-driven protein design and high-throughput data generation presents challenges in automated laboratory systems, robotic sample handling, and closed-loop experimental platforms where computational predictions feed back into physical experimentation cycles. The integration of machine learning models with wet-lab automation is a core operational requirement.